SOURCE-LINKED STUDY SUMMARY
Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.
Abstract summarizedQuality not appraised
- What was studied
- A retrospective US database study compared tirzepatide with other GLP-1 receptor agonists for inflammatory bowel disease outcomes over 18 months.
- Who / model studied
- After matching, each group contained 3,042 adults; average age was 54.6 years and 71.3% were women.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Tirzepatide was associated with less intravenous steroid use and fewer combined steroid-or-surgery events. Hospitalization, emergency visits, intestinal surgery and adverse-outcome risks were similar between groups.
- Limitations & context
- The authors call for prospective studies to validate these associations.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.5217/ir.2026.00152